Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Lyft Announces Private Offering of $450 million of Convertible Senior Notes

(NASDAQ:LYFT) SAN FRANCISCO--(BUSINESS WIRE)--Lyft, Inc. (“Lyft”) (NASDAQ: LYFT) today announced its intention to offer, subject to market conditions and other factors, $450 million aggregate princ...

What specific use‑of‑proceeds guidance did Lyft provide, and what impact could the net proceeds have on its liquidity profile and near‑term operational initiatives? What are the conversion terms and credit spread of the 2030 senior notes, and how do they compare to current market rates for similar high‑growth tech issuances? How will the $450 million convertible note issuance affect Lyft’s capital structure and dilution risk for existing shareholders?
Symbol: LYFT
Debt offering
13 days ago
Read more businesswire

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

(NASDAQ:ZENA) - Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -

What specific milestones and timelines are linked to the funding agreement, and how might meeting or missing them impact Zenas' valuation and risk profile? What is the market size and competitive landscape for obexelimab in IgG4‑Related Disease, and how does this partnership position Zenas against existing therapies? How will the $75 million upfront funding and potential $300 million total commitment affect Zenas' cash runway and dilution profile?
Symbol: ZENA
Funding
13 days ago
Read more globenewswire

More Than 450 Companies Drive Speed to Market with Veeva RIM

(NYSE:VEEV) Advanced regulatory capabilities and new industry partnerships accelerate collaboration with global health authorities BARCELONA, Spain, Sept. 2, 2025 /PRNewswire/ -- Veeva Systems (NYS...

Will the market price the announcement into VEEV's stock immediately, or could there be a delayed reaction based on subsequent client onboarding metrics? What effect will these new industry partnerships and accelerated regulatory capabilities have on VEEV's competitive positioning relative to peers like IQVIA and Medidata? How will the adoption by over 450 companies, especially 19 of the top 20 biopharmas, influence VEEV's revenue trajectory and earnings forecasts?
Symbol: VEEV
Partnerships
13 days ago
Read more prnewswire

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

(NASDAQ:IONS) CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in ...

What is the competitive landscape for severe hypertriglyceridemia therapies, and how does olezarsen’s efficacy and safety profile compare to existing or pipeline competitors? How will the significant reductions in triglycerides and acute pancreatitis events impact Ionis' revenue forecasts and valuation? What is the expected timeline for FDA approval and market launch of olezarsen following these Phase 3 results?
Symbol: IONS
Clinical trials
13 days ago
Read more businesswire